Genenta Science S.p.A. (NASDAQ:GNTA) Short Interest Down 17.1% in May

Genenta Science S.p.A. (NASDAQ:GNTA - Get Free Report) was the target of a significant decline in short interest in May. As of May 15th, there was short interest totalling 2,900 shares, a decline of 17.1% from the April 30th total of 3,500 shares. Approximately 0.0% of the shares of the company are sold short. Based on an average daily volume of 18,500 shares, the short-interest ratio is presently 0.2 days.

Genenta Science Price Performance

NASDAQ GNTA traded down $0.06 on Thursday, reaching $4.30. The stock had a trading volume of 41,168 shares, compared to its average volume of 14,848. Genenta Science has a 12-month low of $2.79 and a 12-month high of $7.28. The business's 50-day moving average price is $4.05 and its 200 day moving average price is $4.27.

Hedge Funds Weigh In On Genenta Science

A number of institutional investors have recently modified their holdings of GNTA. Allianz SE increased its position in Genenta Science by 126.2% in the 1st quarter. Allianz SE now owns 233,550 shares of the company's stock valued at $927,000 after acquiring an additional 130,300 shares during the period. Algebris UK Ltd grew its stake in shares of Genenta Science by 122.2% during the 1st quarter. Algebris UK Ltd now owns 100,000 shares of the company's stock worth $368,000 after purchasing an additional 55,000 shares during the period. Finally, Citadel Advisors LLC acquired a new position in shares of Genenta Science during the 4th quarter worth $46,000. 15.13% of the stock is owned by institutional investors and hedge funds.

About Genenta Science

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.